Cost-Effectiveness Analysis Of Pulmicort-Combivent And Pulmicort Single Use In Inpatients With Chronic Obstructive Pulmonary Disease At Dr. Moewardi Regional Hospital

Yustina Esha Maunia Chantika
Kharisma Jayak Pratama
Vivin Marwiyati Rohmana

International Journal of Health, Engineering and Technology
Vol. 4 No. 6 (2026): IJHET MARCH 2026

Chronic Obstructive Pulmonary Disease (COPD) causes a high economic burden due to repeated hospitalizations, but the cost-effectiveness of Pulmicort-Combivent versus Pulmicort alone has not been evaluated at Dr. Moewardi Regional General Hospital. This study aims to determine ACER, ICER, and cost-effectiveness of therapy using CEA. This study was a retrospective, descriptive, cross-sectional observational study with a total sampling of 62 hospitalized COPD patients from January 2024 to November 2025. Medical record data instruments were analyzed using ACER, ICER, and the Mann-Whitney test. The results showed that the ACER of Pulmicort-Combivent Rp225,775 (40% effectiveness) was lower than that of Pulmicort alone Rp765,036 (14.03%), ICER Rp-65,554, with no significant difference (p>0.05). Both therapies were equivalent in terms of cost-effectiveness.